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Abstract
As global populations continue to age, the prevalence of
neurodegenerative disorders, such as Alzheimer’s and
Parkinson’s disease, will continue to increase. A late onset
symptom of neurodegenerative disease is locomotive defects.
While many genes have been identified through whole exome
sequencing as playing a role in human locomotion, little is
known about what role they play in normal function.
Dependable assays are needed to better understand the
functions of these genes. However, modeling these diseases
in vitro, to better understand, treat, and prevent them, has
proven to have limitations. The isolated reality of cultures
prevents an accurate simulation of the responses that would
take place in the organism, such as physiological pathways
and responses and non-autonomous cellular influences.
Additionally, while mammalian models are important, they also
can be prohibitive due to related costs and the length of time
required. Fortunately, many of the issues these frameworks
present have a small, but powerful answer: Drosophila
melanogaster. Flies are easily genetically manipulated, allow
for pathological observation, are inexpensive to care for, have
short lifespans of about 40 days, and have an ortholog for
approximately 75% of human genes known to cause disease.
(Marsh, 2006)
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Experiments Proposed
The experiments proposed include both a forward and reverse genetic screen, using
both unknown mutants and known neurodegenerative mutants, respectively, to search
for locomotory defects. The trial results will be compared to wild type and known
locomotory-defective mutants. We will perform statistical analysis, using students t-test
and ANOVA methods. We will also look for reduced lifespan in forward screened
mutants, and this will be assessed separately. Once data is collected, we will further
characterize these genes in our Drosophila model of neurodegeneration. We hope to
uncover a novel gene involved in neurodegeneration with our project.
Methods
 Obtain flies for blind mutant screen
 Obtain flies with known genetic mutations
Figure 1.
Experimental
setup for climbing
assays

Through the use of the GAL4-UAS system, flies can be
“humanized” with a gene known to affect the brain. (Marsh,
2006). The genes will be fully characterized using behavioral
and cellular assays. By observing the behavioral phenotypes
of these mutants, as they age, with a negative geotaxis
(climbing) assay, genetic targets of therapeutic interest can be
identified. (Madabattula, 2015)

Background
Generally speaking, neurodegenerative diseases involve
the degradation, and death, of neurons. Since the first
description of a transgenic Drosophila model of a human
degenerative disease in 1998, the use of fly models has
grown rapidly. Diseases modeled include dominant
polyglutamine-repeat diseases, tauopathies, Alzheimer’s
disease (AD), Parkinson’s disease (PD), and expanded
triplet-repeat diseases in noncoding DNA. (Marsh &
Thompson, 2006) By taking advantage of flies’
predisposition to climb, or negative geotaxis, locomotive
defects can be measured and quantified over time. Using
mutant Drosophila models allows genes of therapeutic
interest to be identified as the mechanism of the climbing
defect is discovered.

Figure 2. Schematic representation of genetic tools used in
these experiments

 Rear flies to obtain correct genotype for assay
 Collect flies of correct genotype, sex, and age
 Setup climbing assay
o Transfer flies into climbing tube and seal with barrier
o Setup camera focused 10 cm from the bottom
o Begin recording
o Gently tap tube on foam pad to displace flies to bottom
o Conduct each trial for 2 minutes from last tap
o With fresh tube, repeat 10 times for each genotype
 Average numbers of flies per trial to pass 10 cm
 Analyze the videos by recording the total number of flies that pass the target line
 Analyze performance using statistical analysis, such as student t-test and ANOVA
 Add candidate genes to list for further characterization

Wild type
Predicted Results
We anticipate the forward genetic screen will
result in a collection of neurodegenerative
mutants. Our reverse genetic screen will confirm
previous hypotheses as to the nature of the
mutation and its effects on behavior. We will
further analyze general behavior, including
mating, socializing, feeding, and lifespan, of all of
these mutants. Our long-term goal is to
Mutant
characterize these genes in working models of
physiology and morphology associated with
neurodegeneration, and ultimately to provide
Figure 3. Predicted results: a decrease in
therapeutic insights for mammalian models of
climbing ability due to the mutation of a gene
brain diseases.
putatively involved in neurodegeneration
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